UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Sep

    28

    Employee Spotlight: Jessie Kim's Journey as a Global Regulatory Fellow

    Read More Share:linkedin| twitter| email

    Sep

    12

    Disease Spotlight: Thymidine Kinase 2 Deficiency (TK2d)

    Read More Share:linkedin| twitter| email

    Sep

    11

    UCB PharmD Second-Year Fellows Share Reflections and Advice

    Read More Share:linkedin| twitter| email

    Sep

    05

    Announcing the 2023 UCB Family Epilepsy Scholarship Winners

    Read More Share:linkedin| twitter| email

    Aug

    28

    Breaking Down the Value Chain: Patient Voices Advocating for Change

    Read More Share:linkedin| twitter| email

    Aug

    03

    Employee Spotlight: David Hornbaker’s Heart for Helping Patients

    Read More Share:linkedin| twitter| email

    Aug

    01

    Evolving Expectations for Dermatological Conditions

    Read More Share:linkedin| twitter| email

    Jul

    21

    UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

    Read More Share:linkedin| twitter| email

    Jun

    27

    Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

    Read More Share:linkedin| twitter| email

    Jun

    27

    UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)